Ge Long Hui·2026-02-04 03:29Core Viewpoint - The report from Citi indicates that JD Health is expected to maintain growth momentum in the second half of last year, driven by strong performance during the Double Eleven sales event and a surge in flu cases in December [1] Financial Performance - Revenue is projected to increase by 24.5% year-on-year to 37.1 billion yuan [1] - Adjusted EBIT is expected to double year-on-year to 2.1 billion yuan, supported by margin expansion and operational leverage [1] Profit Forecast - Citi has raised JD Health's adjusted net profit forecasts for the fiscal years 2026 and 2027 by 1% and 2% respectively, reflecting the recovery in drug sales and profit expansion prospects [1] - The firm maintains a "Outperform" rating and sets a target price of 71 HKD for JD Health [1]